HeartBeam Upgraded to Buy as Joseph Gunnar Report Cites Commercialization Momentum

Joseph Gunnar & Co. upgraded HeartBeam from Hold to Buy and raised its 12-month price target to $4 from $1, citing regulatory progress and the company's transition toward commercialization. The February 2026 research report characterizes the FDA clearance of HeartBeam's 12-lead ECG synthesis software for arrhythmia assessment as a critical regulatory milestone. The upgrade reflects growing confidence in the company's commercial launch strategy and long-term opportunity in cardiac risk detection.

HeartBeam will introduce its FDA-cleared cable-free, synthesized 12-lead ECG system designed to deliver clinical-grade cardiac insights for arrhythmia assessment in a portable format. The research report underscores the company's targeted go-to-market strategy, highlighting a significant turning point following regulatory approval. Equity research reports often serve as important barometers of shifting sentiment, offering investors detailed analysis of a company's strategy, risks and growth potential.

The report states that the upgrade to a BUY and High-Risk rating with a raised price target reflects progress in cardiac risk detection. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT. BioMedWire is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors, and is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers various distribution services.

For more information about BioMedWire's services, please visit https://www.BioMedWire.com. The full terms of use and disclaimers applicable to all content provided by BMW are available at https://www.BioMedWire.com/Disclaimer. The upgrade represents a vote of confidence in HeartBeam's ability to commercialize its medical technology and capture market opportunity in portable cardiac monitoring solutions.